Bedrijfsoverzicht
Puma Biotechnology, Inc. is a biopharmaceutical enterprise dedicated to the development and commercialization of products designed to enhance cancer care within the United States and international markets. The company operates specifically within the healthcare sector, functioning in the specialized industry of biotechnology, which focuses on biological innovations for medical applications. In terms of scale, the entity holds a market capitalization of $395.82M, generates annual revenue of $228.37M, and employs a workforce of 179 individuals. These financial figures indicate that the company operates as a mid-sized entity within the biotechnology landscape, possessing sufficient revenue to sustain operations while maintaining a market valuation that reflects its potential for growth in the oncology space. The employee count of 179 suggests a lean operational structure typical of many biotech firms that prioritize research and development efficiency over large-scale administrative overhead.
Financiële gezondheid
The company reported a total revenue of $228.37M for the trailing twelve months, with a corresponding net income of $31.11M and an EBITDA of $47.44M. The significant gap between the $228.37M revenue and the $31.11M net income reveals a substantial cost structure, where operating expenses and taxes consume a considerable portion of gross earnings before arriving at the bottom line. However, the EBITDA figure of $47.44M provides a clearer picture of operational profitability before the impact of financing and non-cash items like depreciation. The free cash flow stands at $30.69M, which indicates that the company generates positive cash flow after capital expenditures, granting it financial flexibility to fund research, development, or potential strategic acquisitions without immediate reliance on external financing. Analyzing the margins, the gross margin is 74.5%, indicating high efficiency in production relative to sales; the operating margin is 22.7%, reflecting a healthy ability to control overhead costs; and the profit margin is 13.6%, which demonstrates the final profitability available to shareholders after all expenses. Regarding liquidity and leverage, the company holds $97.53M in cash against $28.55M in debt, resulting in a debt-to-equity ratio of 21.90%, which suggests a balance sheet that is relatively leveraged in terms of debt relative to equity, yet well-capitalized due to the substantial cash reserves. The current ratio is 2.00, indicating that the company possesses twice as many current assets as current liabilities, which points to strong short-term liquidity and a robust ability to meet its obligations. Furthermore, the Return on Equity is 28.0% and the Return on Assets is 10.9%, metrics that reveal management's effectiveness in generating returns from shareholder investments and utilizing the company's asset base efficiently.
Waarderingsbeoordeling
The trailing P/E ratio is 12.75, while the forward P/E is 11.97, and the difference between these two figures implies that the market expects earnings to increase slightly in the coming year. The price-to-book ratio stands at 3.01, indicating that the market values the company at a significant premium over its book value, likely due to the intangible value of its intellectual property and pipeline potential. Alternative valuation metrics such as the price-to-sales ratio of 1.73 and the EV/EBITDA of 6.89 provide additional context, suggesting that the stock is priced moderately relative to its sales revenue and enterprise earnings before interest, taxes, depreciation, and amortization. The 52-week high is $7.90 and the 52-week low is $2.75, meaning the current trading price sits within this established range, reflecting recent market volatility within the sector. The beta value is 1.18, which explains that the stock's price volatility is higher than the broader market, making it more sensitive to general market movements than a stock with a beta of 1.00.
Growth & Income
The revenue growth year-over-year is 27.7%, whereas the earnings growth year-over-year is -34.4%, indicating that earnings are currently growing slower than revenue, which implies that the company is reinvesting heavily in operations or facing temporary headwinds in profitability despite top-line expansion. As a non-dividend payer, the company does not distribute a dividend yield, evidenced by a payout ratio of 0.0%, which means the company retains all of its earnings to reinvest into growth initiatives rather than paying dividends to shareholders. This approach prioritizes funding future product development and clinical trials over immediate income distribution to investors. Summarizing the profile, the company exhibits strong top-line expansion but faces a temporary contraction in earnings growth, while its income strategy focuses entirely on capitalizing on future commercialization rather than current cash returns.